ORPHA:2122
Kaposiform hemangioendothelioma
Publications
1,218
Trials
11
Interventional, condition-specific
Researchers
1,017
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare, locally aggressive, cutaneous or visceral vascular tumor characterized by either superficial lesions presenting as blue-purple infiltrated ill-defined plaques, or deep lesions usually manifesting with coagulation abnormality. They are associated in about 3 out of 4 of cases with potentially lethal thrombocytopenia and consumption coagulopathy (Kasabach-Merritt phenomenon; KMP).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016236
- MeSH:C537007
- UMLS:C1367420
- NCIT:C27510
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,218 matched papers (831 in last 10 years) Source
- Phenotype characterisedPresent
14 HPO annotations (e.g. Chronic disseminated intravascular coagulation; Hypofibrinogenemia; Pain) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
11 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
14
Associated phenotypes · MONDO:0016236
- Chronic disseminated intravascular coagulation
- Hypofibrinogenemia
- Pain
- Erythematous plaque
- Petechiae
Showing 5 of 14 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0016236
- PREDNISOLONE·phase 2
- TACROLIMUS·phase 2
- VINCRISTINE·phase 2
- METHYLPREDNISOLONE·phase 1
- PREDNISONE·phase 1
- SIROLIMUS·phase 2 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,218
1,218 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,218 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
831 in the last 10 years · low confidence
Phrase hits: 1,218 · MeSH hits: 0
Who's working on it?
1,017
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ji Y19 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 02Zhou J15 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 03Qiu T12 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 04Chen S10 papers · 2026
Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 05Lan Y10 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 06Zhang Z9 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 07Gong X8 papers · 2026
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 08Zhang X8 papers · 2026
Division of Oncology, Department of Pediatric Surgery and Med-X Center for Informatics, West China Hospital of Sichuan University, Chengdu, China.
Papers in Europe PMC - 09Zhang Y8 papers · 2026
Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, China.
Papers in Europe PMC - 10Wang Z7 papers · 2026
Department of Pediatric Surgery, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
11
interventional trials for this specific condition
11 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 13 trials are registered for hemangioendothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
11 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.8th percentile).
low confidence · 92.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
11 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07131644·NOT YET RECRUITING·Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
Not reviewed·Conditions: Kaposiform Hemangioendothelioma·Matched via name phrase
- NCT07656909·RECRUITING·Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Not reviewed·Conditions: Kaposiform Hemangioendothelioma (KHE) · Kasabach Merritt Phenomenon·Matched via name phrase
Broader category: hemangioendothelioma
13
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07104331·RECRUITING·SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Not reviewed·Conditions: Epithelioid Hemangioendothelioma (EHE)·Matched via name phrase
- NCT07684287·NOT YET RECRUITING·A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Not reviewed·Conditions: Epithelioid Hemangioendothelioma·Matched via name phrase
- NCT07477548·NOT YET RECRUITING·A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Not reviewed·Conditions: Vascular Malformations · Arteriovenous Malformations · Venous Malformation · Lymphangioma·Matched via name phrase
- NCT06452160·RECRUITING·A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Not reviewed·Conditions: Mesothelioma · Epithelioid Hemangioendothelioma(EHE) · Solid Tumor·Matched via name phrase
- NCT03967834·RECRUITING·Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Not reviewed·Conditions: Soft Tissue Sarcoma · Clear Cell Sarcoma · Epithelioid Sarcoma · Perivascular Epithelioid Cell Neoplasms·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05351216·RECRUITING·The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
Not reviewed·Conditions: Kaposiform Hemangioendothelioma·Matched via name phrase
- NCT02399527·RECRUITING·Lymphatic Anomalies Registry for the Assessment of Outcome Data
Not reviewed·Conditions: Lymphatic Malformation · Generalized Lymphatic Anomaly (GLA) · Central Conducting Lymphatic Anomaly · CLOVES Syndrome·Matched via name phrase
- NCT03001180·RECRUITING·Identification of Biomarkers for Patients with Vascular Anomalies
Not reviewed·Conditions: Vascular Anomaly · Generalized Lymphatic Anomaly · Kaposiform Hemangioendothelioma · Kaposiform Lymphangiomatosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Kaposiform hemangioendothelioma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Kaposiform hemangioendothelioma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Kaposiform hemangioendothelioma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 11 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemangioendothelioma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1218) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T19:11:14.863Z
